GE Healthcare has completed a licence agreement with NorDiag granting it access to GE Healthcare patents for the biomagnetic isolation of nucleic acids
The licence, which is valid for the lifetime of the patents, grants NorDiag certain rights with respect to the isolation and purification of nucleic acids using GE Healthcare's proprietary magnetic separation technology.
GE Healthcare's patented methods for magnetic separation offer significant advantages over conventional techniques for the isolation and purification of biomolecules such as DNA and RNA from laboratory and clinical samples.
In particular, the proprietary protocols will allow diagnosis from smaller-volume patient samples because they increase the yield of nucleic acid from disease-causing pathogens isolated from patient samples.
"This licence recognises the considerable value that our biomagnetic isolation technology can bring to the diagnosis of infectious diseases," said Eric Roman, general manager, Genomic Sciences, GE Healthcare.
"We are pleased to grant NorDiag access to our patents in this area, which will allow it to commercialise products that can isolate nucleic acids from difficult clinical samples".
"The licence from GE Healthcare is important for us since it enables us to widen our portfolio of products for clinical diagnostics," said Marten Wigstol, CEO, NorDiag.
"It also shows shareholders that we have the capability to bring in external technologies from large players such as GE Healthcare to strengthen our technology base".
GE Healthcare has an active programme to grant licences for access to its patents for biomagnetic isolation.
